ES2065369T3 - Uso de bencimidazoles en el tratamiento de enfermedades epiteliales. - Google Patents

Uso de bencimidazoles en el tratamiento de enfermedades epiteliales.

Info

Publication number
ES2065369T3
ES2065369T3 ES89203001T ES89203001T ES2065369T3 ES 2065369 T3 ES2065369 T3 ES 2065369T3 ES 89203001 T ES89203001 T ES 89203001T ES 89203001 T ES89203001 T ES 89203001T ES 2065369 T3 ES2065369 T3 ES 2065369T3
Authority
ES
Spain
Prior art keywords
effective amount
benzmidazoles
treatment
isomeric form
stereochemically isomeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89203001T
Other languages
English (en)
Inventor
Wauwe Jean P F Van
Alfons H M Raeymaekers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2065369T3 publication Critical patent/ES2065369T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE EL USO Y FABRICACION DE UN MEDICAMENTE PARA EL TRATAMIENTO DE LAS ENFERMEDADES EPITELIALES DE LA PIEL DE BENZIMIDAZOLA O BENZOTRIAZOLA DE LA FORMULA (I), (II) EN DONDE -A1=A2-A3=A4- ES -CH=N-CH=CH-; -CH=N-CH=N; O -CH=N-N=CH-; R ES HIDROGENO O ALKIL C1-C6; R1 ES HIDROGENO, ALKIL C1-10; CICLOALKIL C3-7; ALKIL AR1-C1; R2 ES HIDROGENO; CICLOALKIL C3-7AR1; ALKIL C1-10; ALKIL C1-6 SUSTITUIDO CON AR1 O CICLOALKIL C3-7; HIDROXIDO; ALKILOXIDO C1-10; ALKILOXIDO C1-6 SUSTITUIDO CON AR1 O CICLOALKIL C3-7; ALKENILOXIDO C3-6 OPCIONALMENTE SUSTITUIDO CON AR2., ALKINILOXIDO C3-6 OPCIONALMENTE SUSTITUIDO CON AR2.; O AR1-OXIDO; LAS SALES DE ADICCION ACIDA FARMACEUTICAMENTE ACEPTABLES Y LAS FORMAS POSIBLES ESTEREOQUIMICAMENTE ISOMERICAS DEL MISMO; COMPUESTOS FARMACEUTICOS QUE CONTIENE DICHOS COMPUESTOS COMO INGREDIENTES ACTIVOS Y METODOS PARA PREPARAR DICHOS COMPUESTOS Y COMPUESTOS FARMACEUTICOS; COMPOSICIONES CONTENIENDO LOS INGREDIENTES ACTIVOS (I) Y/O (II) Y EL ACIDO RETINOICO O UN DERIVATIVO DEL MISMO.
ES89203001T 1988-11-29 1989-11-27 Uso de bencimidazoles en el tratamiento de enfermedades epiteliales. Expired - Lifetime ES2065369T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27715288A 1988-11-29 1988-11-29

Publications (1)

Publication Number Publication Date
ES2065369T3 true ES2065369T3 (es) 1995-02-16

Family

ID=23059616

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94200665T Expired - Lifetime ES2173902T3 (es) 1988-11-29 1989-11-27 Composiciones topicas que contienen bencimidazoles y benzotriazoles.
ES89203001T Expired - Lifetime ES2065369T3 (es) 1988-11-29 1989-11-27 Uso de bencimidazoles en el tratamiento de enfermedades epiteliales.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94200665T Expired - Lifetime ES2173902T3 (es) 1988-11-29 1989-11-27 Composiciones topicas que contienen bencimidazoles y benzotriazoles.

Country Status (16)

Country Link
EP (2) EP0609963B1 (es)
JP (2) JP2752200B2 (es)
AT (2) ATE112681T1 (es)
AU (2) AU623454B2 (es)
CA (1) CA2002859C (es)
CY (1) CY1867A (es)
DE (2) DE68918809T2 (es)
DK (1) DK175793B1 (es)
ES (2) ES2173902T3 (es)
HK (1) HK114895A (es)
IE (1) IE63877B1 (es)
IL (1) IL92487A (es)
NZ (1) NZ231405A (es)
PT (1) PT92449B (es)
SG (1) SG50466A1 (es)
ZA (1) ZA899074B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
JPH08502990A (ja) * 1992-11-10 1996-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 鏡像体的に純粋な６−［（４−クロロフェニル）（１ｈ−１，２，４−トリアゾール−１−イル）メチル−１−メチル−１ｈ−ベンゾトリアゾールの製造方法
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CN1141042A (zh) * 1994-02-18 1997-01-22 詹森药业有限公司 旋光对映纯的(+)-利罗唑
MX9603510A (es) * 1994-02-18 1997-03-29 Janssen Pharmaceutica Nv (-)-liarozol enantiomericamente puro.
WO1996019991A1 (en) * 1994-12-28 1996-07-04 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
TW316902B (es) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
WO1997006788A1 (en) * 1995-08-14 1997-02-27 Janssen Pharmaceutica N.V. Transdermal administration of vorozole
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
JP3404749B2 (ja) 1996-06-27 2003-05-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｎ―［４―（ヘテロアリールメチル）フェニル］―ヘテロアリールアミン
JPH10220909A (ja) 1996-12-03 1998-08-21 Komatsu Ltd 流体温度制御装置
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PT1037880E (pt) 1997-12-11 2004-11-30 Janssen Pharmaceutica Nv Anilidas mimeticas do acido retinoico
EP1097150B1 (en) * 1998-06-16 2004-03-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
WO2000066077A1 (en) * 1999-04-29 2000-11-09 Avon Products, Inc. Method of improving the aesthetic appearance of epithelia
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
FR2815857B1 (fr) * 2000-10-30 2003-02-14 Oreal Composition, notamment cosmetique, renfermant un retinoide et une silicone benzotriazole
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP1558341A4 (en) * 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
CA2785536C (en) 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
DK2723741T3 (en) 2011-06-24 2016-06-06 Arqule Inc SUBSTITUTED imidazopyridinyl-aminopyridine compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders

Also Published As

Publication number Publication date
DE68929377T2 (de) 2002-10-31
CA2002859C (en) 1998-12-29
JPH1095782A (ja) 1998-04-14
ATE112681T1 (de) 1994-10-15
EP0371559A3 (en) 1992-04-08
HK114895A (en) 1995-07-21
EP0371559A2 (en) 1990-06-06
DE68918809T2 (de) 1995-03-23
PT92449A (pt) 1990-05-31
AU623454B2 (en) 1992-05-14
IL92487A0 (en) 1990-08-31
IE63877B1 (en) 1995-06-14
ZA899074B (en) 1991-07-31
IL92487A (en) 1994-12-29
JPH0320273A (ja) 1991-01-29
CY1867A (en) 1996-04-05
PT92449B (pt) 1995-07-18
DK175793B1 (da) 2005-02-21
DE68918809D1 (de) 1994-11-17
DK599589D0 (da) 1989-11-28
ES2173902T3 (es) 2002-11-01
SG50466A1 (en) 1998-07-20
AU4564889A (en) 1990-06-07
EP0609963A1 (en) 1994-08-10
EP0371559B1 (en) 1994-10-12
AU630579B2 (en) 1992-10-29
DK599589A (da) 1990-05-30
EP0609963B1 (en) 2002-03-06
CA2002859A1 (en) 1990-05-29
ATE213941T1 (de) 2002-03-15
IE893781L (en) 1990-05-29
JP2912596B2 (ja) 1999-06-28
IE950033L (en) 1990-05-29
JP2752200B2 (ja) 1998-05-18
NZ231405A (en) 1991-08-27
AU1071692A (en) 1992-03-19
DE68929377D1 (de) 2002-04-11

Similar Documents

Publication Publication Date Title
AU623454B2 (en) Method of treating epithelial disorders
PT723540E (pt) Compostos triciclicos de amida e ureia uteis para inibicao da funcao da g-proteina e para o tratamento de doencas proliferativas.
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
ATE150301T1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen
AU586808B2 (en) Purine derivatives
FI903571A0 (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
ES2054011T3 (es) Un proceso para la preparacion de un compuesto, "leualacina".
ATE274905T1 (de) 4,5-dihydroxy-2-cyclopentene-1-on für die behandlung von rheumatismus, entzündungen und autoimmunerkrankungen
FI901883A0 (fi) Menetelmä terapeuttisesti vaikuttavien 2-substituoitujen N,N'-ditrimetoksibentsoyylipiperatsiinien valmistamiseksi
ATE73330T1 (de) Verwendung von pharmaceutischen zusammensetzungen fuer die herstellung von arzneimitteln fuer die behandlung psychiatrischer stoerungen.
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ATE167869T1 (de) Thiolderivate von gallensäure
MX9603316A (es) (+)-liarozol enantiomericamente puro.
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
AU2013888A (en) Uricosuric composition
JPS6452772A (en) Pyridylpyrimidine derivative, production thereof and plant disease controlling agent containing said derivative as active ingredient
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
GR74444B (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 371559

Country of ref document: ES